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The burden of diseases in India – in the light of health 
care financing
India is struggling not only against communicable 
diseases but also carries a large burden of non-commu-
nicable diseases. India is one of the 10 countries hosting 
75% of the children who had not received vaccines for 
vaccine preventable diseases, like diphtheria, pertusis 
and tetanus. The diseases caused by Haemophilus, Pneu-
mococcus and Rotaviruses, which are causing 2.1 mil-
lion deaths in all age groups worldwide, have not even 
nudged the Indian government to provide access to the 
appropriate vaccines [1]. For the pharmaceutical indus-
try, R&D (research & development) on vaccines is not 
that profitable as the purchases are made by the govern-
ment and moreover, the use is only for one time. There is 
a lack of vaccine coverage in the developing world and 
there is a growing need for developing new and better 
vaccines.
The epidemiologic status of India with regard to the 
infectious diseases is no different. The so called diseases 
of the poor, namely malaria, tuberculosis, leprosy, leish-
maniasis, dengue and lately HIV and AIDS have added 
a severe toll on the country’s health status. Malaria is 
killing around 1 million people worldwide [2]. It is af-
fecting the most vulnerable population and has severe 
impact on the overall economic growth of many nations 
[3]. Most of the drugs used in malaria are reportedly 
becoming less effective due to the drug resistance. It 
has been ages since any major breakthroughs have been 
made in the treatment of this disease.
India has got the largest burden of tuberculosis (TB) 
in the world. TB is killing an individual every two min-
utes. In recent times the situation has only worsened with 
the co-occurrence of TB and HIV. To add to this insult, 
the incidence of drug- and multi-drug-resistant TB is on 
the rise. The prime reason is irregular or only partial 
treatment. The diagnosis, treatment and even the vaccine 
are dependent on old and imperfect technologies [4].
Over the last few years a growing number of people 
have been infected with HIV. Poor countries have the 
highest patient load and India carries the third largest 
burden of HIV cases. The number of people dying from 
AIDS is on a constant rise. Irrespective of the current 
scenario there is still limited or no access to antiretrovi-
ral therapy in many nations [5]. In the recent times many 
of the toughest IPR (Intellectual Property Rights) legal 
battles have been fought over access to the anti-retroviral 
therapies (ARTs) for people living with HIV and AIDS. 
Millions of these people in the countries bearing the 
maximum burden of the disease have been treated with 
generic drugs manufactured just in India. The Indian 
pharmaceutical manufacturers like CIPLA have been 
offering ART drugs at as low price as $ 350 per year in 
comparison with that of $ 10,000 per year as priced by 
the Western drug industry. Competition caused by the 
Indian generic manufacturers managed to bring down 
the prices by around 98% but since their accession to the 
TRIPS accord (see below), the Indian manufacturers are 
forced to withhold their exports, resulting in millions of 
people waiting or perishing in need for the therapy [6].
The situation of other neglected diseases affecting 
the poor people is identical. These diseases are peculiarly 
having a large prevalence in the low-income developing 
world, a lower burden in the developed nations, and a low 
level of funding in comparison to the disease burden. As 
with most of the neglected diseases, the apparent lack of 
a profitable consumer market for appropriate drugs and 
the fact that the neglected diseases concern the develop-
ing countries, are used to explain the relatively low level 
of R&D investment of the pharmaceutical giants. This 
under-funding of research in the area of the neglected 
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diseases of the poor is known as the “10/90 gap” which 
refers to the point that lesser than 10% of the global R&D 
expenditure is devoted to the diseases and conditions as-
sociated with 90% of the world population [7].
Sadly, it is the low and middle income countries that 
are bearing the double brunt of communicable and non-
communicable diseases. India has already become the 
diabetes capital of the world and at the same time India 
loses around 2.5 million people to malaria, respiratory 
infections, diarrhea and other infections, annually [8].
The lack of the access to essential medicines is the 
worst in India and Africa. Ironically, 15% of the entire 
world’s population, most of them living in the developed 
countries, consumes 91% of the drugs produced [9]. 
WHO estimates that the prompt diagnosis and the appro-
priate management with the use of medicines can save 
around 4 million lives annually in South-East Asia and 
Africa [10]. The data on the global spending on drugs 
shows that most of the drug sale is done in the develo-
ped world with the USA leading in statistics, with share 
of almost half of the total sales. The USA, Europe and 
Japan together account for almost 86%. The global share 
of developing countries, like India and Africa together 
is just 2.3% [11].
The UN Millennium Project identified the six most 
important hurdles in accessing health care; four of them 
were on already existing medicines and two were related 
to the development of the cost-effective new medicines 
and vaccines. The report emphasizes that the developed 
nations failed to keep their promises in providing ad-
equate monetary and technical support to the developing 
world. It has also pointed out that the TRIPS agreement 
may cause an additional blockade in accessing new 
therapies and vaccines at affordable prices. It would be 
having a major impact on countries like India, as this 
country would no longer be able to produce or supply the 
vital generic drugs, not only to their local markets but 
also to their African counterparts. Moreover, the exist-
ing incentives in the developing world are insufficient 
to foster research and inventions for diseases specific 
to these countries. However, the “Doha Declaration on 
TRIPS and Public Health” restated and re-affirmed that 
the public health matters override the IPR matters and 
that the member States can take all necessary measures 
to ensure the same. In fact, this is highly questionable.
As in many developing countries, the private expen-
diture on health in India is higher than the government 
contribution. Another important feature is that only 
4.8% of the GDP is the overall contribution towards he-
alth. The trend in India is discouraging, as in addition 
to the low total expenditure on health as a percent of the 
GDP, the central government spending is also on decline. 
Therefore it is clear that the majority of health care fun-
ding in India comes in fact from the out-of-pocket (OOP) 
expenses, making the health care system in India one of 
the world’s most privatized. It is amazing to find that 
the private OOP expenses on medicines take the largest 
share of households expenditures in many developing 
countries. They may go from 50% to as high as 90% of 
the sales of medicines [12]. Drugs form the majority of 
the OOP expenses in health care expenditures of India. 
The average OOP expenses are estimated to be in the 
range of 80.9% of the total private health expenditures. 
The total public health expenditure is less than 10% on 
drugs.
 
In India 26% of the population live below the poverty 
line. The poor lack the access to essential medicines for 
many reasons, all of which must be addressed in a com-
prehensive manner. The most important reason, by far, is 
the poverty itself, which means that neither the poor nor 
their governments can afford to purchase the essential 
medicines or ensure their proper use in well – run health 
care systems. It is important to say that the Indian health 
care system uses very little governmental funding and it 
is predominantly privately owned and based on the OOP 
financing.
The data from Tables I and II (below) allow to make 
some comparisons and reflect the characteristics of the 
health care financing in India and on the position of the 
Indian subcontinent’s pharmaceutical market.
Region 2004 2005
Global share 
of sales 2005 
(%)
North America 249.0 268.8 44.4
Europe 169.2 180.4 29.8
Japan 66.1 69.3 11.4
Oceana 7.1 7.7 1.3
CIS 4.2 5.0 0.8
South-east Asia 25.3 28.8 4.6
Latin America 24.4 26.6 4.4
Indian sub-continent 6.6 7.2 1.2
Africa 6.3 6.7 1.1
Middle-east 4.7 4.9 0.8
Total world Market 562.9 605.4 100.0
Table I. Global pharmaceutical market by region, USD billion, 
ex manufacturer prices (Bloom B.R. et al., 2006). 
Country HDI rank
Health expenditure
Public (%)
of GDP
Private (%)
of GDP
Per capita
(PPP USS)
United States 8 6.8 8.4 5,711
Korea, Rep. of 26 2.8 2.8 1,074
Brazil 69 3.4 4.2 597
Thailand 74 2.0 1.3 260
China 81 2.0 3.6 278
India 126 1.2 3.6 82
Table II. Expenditure on health of some selected countries in 
2003 (WHO report, 2006).
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The international dimension of the intellectual property 
rights
The intellectual property rights (IPR) are the rights 
granted to a person or an industry for their innovation 
or creation. This allows the innovators to prevent others 
from unsanctioned use of their products, in terms of 
manufacturing, selling, distributing, procuring and ex-
porting; usually for a timeframe of 20 years. To obtain 
these rights the innovator should reveal the information 
on which the invention is based. These rights provide an 
opportunity to the manufacturer, to produce the drugs 
without any competition and at prices determined on 
their own terms. This will enable the innovators to recu-
perate costs invested into the research and development 
of their products and to gain the net profits.
In 1947, 23 nations reached the General Agreement 
on Trade and Tariffs (GATT) to promote and regulate 
the international trade [13]. In 1995, the World Trade 
Organization (WTO) was created to succeed the GATT. 
Currently the WTO has 141 member countries, inclu-
ding India. According to the WTO treaty all members 
must introduce patent regime for product and/or process 
in accordance with the trade-related aspects of the in-
tellectual property rights (TRIPS). To enforce this, the 
uniform standards were set by all member nations so as 
to strengthen and harmonize the protection of the IPR. 
The agreement was relevant also for the production of 
pharmaceuticals. The agreement gave different dead-
lines to different countries depending on their stage of 
development. India had to comply with the regulations 
by 1st January 2005 [14], which meant that one decade 
was given to India to adopt laws for protecting the IPR. 
Several factors (the continuous advancement in science; 
the new breakthroughs in bio-technology; the growing 
participation of the private sector in the cost-intensive 
research and development activities performed in the 
knowledge-based pharmaceutical sector; the relative 
strength demonstrated by the developing nations in ad-
opting the results of scientific innovations into their local 
environments) have prompted the industrialized nations 
to seek stronger protection for innovations.
The pharmaceutical sector employs technological 
capabilities that are rooted in innovative drug discovery 
and development activities (product development), tech-
nological capabilities related to discovering different 
processes of producing drugs (process development), and 
finally, technology related to producing and packaging 
formulations (manufacturing). Certain limitations render 
it hard for developing countries to build these capacities 
in the pharmaceutical sector. The developing countries 
accounted for less than 2% of the total number of patents 
during the 1997–1996 period [15]. At the macro level, 
there is a gap between demand for health research and on-
going activities in the sector, a lack of scientific culture 
amongst scientists and researchers (including emphasis 
on collaboration), weak public support and bureaucratic 
rigidity. At the facility level, there are problems related 
to access to information and technological inputs that are 
important for health research, inadequate human capital 
formation, institutional instability and weak infrastruc-
ture. And at the terminal level, the issues of intellectual 
isolation of researchers and lack of incentives for colla-
boration, low salaries, restriction of career growth due 
to bureaucratic bottlenecks, and lack of the on-the-job 
training possibilities, make it hard to create the efficient 
innovative environment.
The entire discussion about the impact of the TRIPS 
agreement on the health system revolves around two 
main opposing arguments. The TRIPS supporters claim 
that enforcing the patent law will spur innovation and 
would provide incentives for new path-breaking rese-
arch. On the other hand, people who are lobbying against 
TRIPS state that it would not only increase the divide 
between the rich and the poor but it would also decrease 
the access to medicines [16]. Unfortunately, there are 
still no documents showing a positive impact of TRIPS 
on spurring the innovative research process although the 
member countries from the third world are also bearing 
the cost of enforcing the TRIPS agreement [17].
The past and the present of the Indian pharmaceutical 
market
Until 2005 India had no exclusive patent protec-
tion. The Indian Patents Act of 1970 aimed to make 
the country self-sufficient in terms of medicines and it 
gave protection related only to process patents. It suited 
the Indian pharmaceutical industry, which exploited it 
by specializing in modifications of the manufacturing 
processes, what popularly came to be known as the “re-
verse engineering” [18]. This served the national interest 
as well, since India could manufacture cheaper generic 
alternatives to many medicines, which were patented in 
other countries. Due to this, the dramatic growth of the 
Indian pharmaceutical industry has been observed in the 
last 30 years. The market structure started to change. 
The share of multinational subsidiaries declined from 
80 to 90% in 1970, to roughly 30% in 2000. Indian firms 
started becoming the major exporters in the global mar-
ket. Indian pharmaceutical industry exported medicines 
at affordable prices to 200 countries across the globe, 
which brought in the foreign exchange to the country. 
Due to the high technical knowledge, entrepreneurial 
skills, state of the art facilities, low clinical studies costs, 
low capital costs and highly skilled labour force, the In-
dian pharmaceutical industry has witnessed a tremen-
dous growth in last decades and it emerged as one of 
the leading industries in the world. India currently holds 
the 4th position in terms of volume and the 13th one in 
terms of production in the world [19] and it secures the 
access to essential medicines in the developing world, 
at a relatively low cost [20]. In the pharmaceutical sec-
tor India is often cited as an example of an “innovative 
developing country” with significant capacity to carry 
out health care innovation. Indian generic firms are an 
important source of medicinal supply both domestically 
and internationally. They presently produce 22% of all 
generic drugs world wide. The total market value is close 
to 8 billion dollars and bulk drugs form almost 40% 
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of the domestic pharmaceutical industry capacity. The 
Mashelkar Committee [27] identifies 5,877 (licensed) 
drug manufacturing units and 10,400 units involved in 
manufacturing of other substances as ancillary units. 
The annual growth rate has been quite high with bulk 
drugs registering the growth of 12.38% and the growth 
of 11.05% in formulations, contributing to a total produc-
tion increase of 11.17%.
Although the growth of the Indian pharmaceuti-
cal market is phenomenal, it is uneven. Ten of the top 
25 drugs sold in India are hazardous, irrational and non- 
essential [21]. Market for drugs is also highly concen-
trated with the substantial market share controlled by an 
average of four to eight companies only. The competition 
is therefore somewhat restricted.
The 1st of January 2005 was a historic deadline for 
the Indian pharmaceutical industry. Before that date 
the “reverse engineering” was a tool in hand of this in-
dustry (based on the patent laws of India of 1970) by 
which the industry could make any patented molecule. 
The drug companies soon became experts in the process 
of reverse engineering and they manufactured in India 
the less expensive copies of the world’s best-selling and 
patent-protected drugs. The Indian industry grew and 
prospered in a highly regulated environment with gov-
ernment price controls on many formulations and bulk 
drugs. Nowadays, under the new patent law of 2005, the 
drug companies are no longer allowed to manufacture 
and market reverse -engineered products originated by 
the foreign drug manufacturers.
In December 2004 the Government of India promul-
gated the ordinance incorporating the product patent 
regime to meet the deadline set by the WTO for protec-
tion of the IPR. The Patent Bill was passed by the Indian 
parliament on 22nd of March 2005 and The President 
of India gave assent to it on 5th of April 2005. Now it is 
known as The Patent (Third Amendment) Act 2005 and 
it extends patent protection offering both product and 
process patents. The earlier patent law of 1970 allowed 
manufacturing generic drugs, offering only the process 
patents. It helped India to emerge as the major producer 
and exporter of pharmaceuticals for the whole world. 
Now the pharmaceutical companies have to make provi-
sions for high inputs into the research area in order to 
develop the new products. Under the new Act the patent 
holder of a product will continue to retain the IPR and 
will have to be compensated if others manufacture its 
product. Any manufacturer of generics can apply to copy 
a patented drug after it has been marketed for three years 
– after paying a reasonable royalty to the patent holder. 
This has brought a new challenge to the Indian industry, 
as it would no longer be able to manufacture generics 
without ensuring royalties to their originators.
Since the Indian industries are important suppliers 
of finished products and low-priced active ingredients, 
both domestically and to many developing and devel-
oped countries, the common fear has been that the new 
patent laws may destroy these industries, leading to the 
increases of drug prices. On the other hand, as a result of 
TRIPS compliance, the Indian pharmaceutical compa-
nies have increased their exports of generic drugs to the 
more regulated markets of the USA and Europe. This has 
also prompted the Indian companies to enter into agree-
ments and mergers for R&D purposes and into other al-
liances. From this point of view the TRIPS agreement 
has indeed done a lot of good to the business community 
and it helped orient the business towards the well de-
veloped markets, with an eye on R&D and innovation. 
The substantially growing list of the companies clear-
ing the American FDA (Food and Drug Administration) 
approval process [22] enhances their chances for con-
tract manufacturing of drugs and for easing the norms 
for exporting drugs to the highly regulated markets of 
the Western world. This would increase the business 
revenues, which are (in principle) re invested into the 
development of new molecules and the product devel-
opment. Also, the TRIPS agreement paves the way for 
exporting drugs to the lower-income countries, which 
cannot afford to buy the compulsory licenses under the 
new regime; facilitating therefore the global distribution 
of drugs.
The TRIPS accord mandates data exclusivity of 
drugs, discouraging this way the low- cost generic pro-
ducers entry into the market. However, the national 
rights of compulsory licensing would counteract in some 
of such situations, especially with respect to drugs used 
in the treatment of HIV infection. Also, it is important 
to mention that the majority of drugs on the WHO ’s list 
of essential drugs (close to 95% of them) are off-patent 
drugs [23]. Therefore, the implementation of new patent 
regimes doesn’t affect prices of the essential drugs. 
The control of drug prices is done by the national 
pharmaceutical pricing authority under the price control 
legislations. However, the new drug price may not be 
exactly determined because of the lack of benchmark 
price. The multi national companies can manipulate im-
port costs, ultimately leading to the cost based on the 
bargaining power of the companies and the government. 
The lack of the developed insurance system and the low 
domestic purchasing power will together force the phar-
maceutical companies to keep market prices as low.
The summary impact of the TRIPS regulations on the 
Indian pharmaceutical industry
The Indian pharmaceutical industry has evolved over 
three phases. The first one was the period prior to 1970, 
when the industry was dominated by a small set of fo-
reign-owned and foreign-controlled firms. The second 
phase, spanning from the second half of the 1970s to 
the early 1990s, was a period during which the industry 
experienced the structural transformation through the 
growth of the Indian generic industry. Much of the credit 
for this development should be taken by the Patents Act 
of 1970. In the third phase, i.e. since the early 1990s, the 
pharmaceutical industry has seen the rapid consolidation 
of generic producers on their positions. The decade of 
the 1990s witnessed the strongest performance of the 
Indian pharmaceutical industry on several fronts [24]. 
Over 20,000 registered pharmaceutical manufacturers 
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exist in the country. The domestic pharmaceuticals in-
dustry output exceeded INR (Indian Rupee) 260 billion 
in the financial year 2002, which accounts for merely 
1.3% of the global pharmaceutical sector. Out of this, 
the bulk drugs account for INR 54 billion (21%) and the 
formulations for the remaining INR 210 billion (79%). In 
financial year 2001 imports were INR 20 billion, while 
exports were INR 87 billion [25]. The Indian pharma-
ceutical sector has come a long way, being almost non-
existing during 1970s, to the position of a prominent 
provider of health care products, meeting almost 95% 
of country’s pharmaceutical needs. The domestic phar-
maceutical output has increased at a compound growth 
rate (CAGR) of 13,7% per annum. Currently the Indian 
pharmaceutical industry is valued at approximately $ 8.0 
billion. As previously stated, globally the Indian indu-
stry ranks 4th in terms of volume and 13th in terms of 
value. The exports constitute almost 40% of the total 
production of pharmaceuticals in India. India’s pharma-
ceutical exports are to the tune of $3.5 billion currently, 
of which formulations contribute to nearly 55% and the 
remaining 45% comes from bulk drugs [26].
The following aspects should be highlighted in 
a SWOT (Strengths, Weaknesses, Opportunities, Thre-
ats) analysis of the Indian pharmaceutical industry im-
pacted by TRIPS in the recent years:
Strengths 
• Cost competitiveness of the Indian pharmaceutical 
industry.
• Well developed industry with strong manufacturing 
base.
• Access to pool of highly trained scientists, both in 
India and abroad.
• Strong marketing and distribution network.
• Rich biodiversity.
• Competencies in chemistry and process develop-
ment.
• Huge advantage of possessing the knowledge of the 
traditional medicine which is accepted by many in 
India and across the world.
Weaknesses 
• Low investments in innovative R&D and lack of 
resources to compete with MNCs (Multi-National 
Companies) for new drug discovery research and to 
commercialize molecules on a worldwide basis. 
• Lack of strong linkages between industry and acade-
mia. 
• Low medical expenditure and healthcare spend in the 
country.
• Production of spurious and low quality drugs tarnishes 
the image of industry at home and abroad. The drug 
control system in India is still poor. The drugs manu-
factured can be re exported after repacking or black 
marketed in other low -income markets and thus result-
ing in the decrease of quality of drugs, more often lead-
ing to the problem of accessing proper drugs in spite of 
availability. India forms the major market for the coun-
terfeit drugs exported to the Third World countries. 
The drug monitoring systems have to be strengthened 
to reduce the problem of the counterfeit drugs.
Opportunities 
• Significant export potential. 
• Licensing deals with MNCs for New Chemical 
Entities (NCEs) and Novel Drug Delivery System 
(NDDS). 
• Marketing alliances to sell MNC products in dome-
stic market. 
• Contract manufacturing arrangements with MNCs.
• Potential for developing India as a centre for inter-
national clinical trials and a niche player in global 
pharmaceutical R&D.
• Supply of generic drugs to developed markets.
• With the accession to the TRIPS agreement, the In-
dian government has opened the door for accessing 
the western markets and many companies are already 
exporting drugs to highly regulated market. This im-
proves quality as more compliance is needed to ad-
here to the FDA standards and maintain good manu-
facturing practices (GMP-s). Also, this has made 
possible for simultaneous availability of the drug in 
multiple markets, cutting down the lag periods in the 
availability, in the low income markets.
• Bigger players on the international pharmaceutical 
market have always focused on the R&D activity 
and are spending on that a significant part of their 
turnover. R&D cost is much lower in India, but only 
a fraction of compounds synthesized is launched 
commercially. An option is for companies to get into 
research exclusively and enter into contracts with 
larger players which the TRIPS agreement is giv-
ing a major boost. With increase of sales and profits, 
some of the money is used to invest in the research 
and development of new methods and drugs.
• More research and facilitation of IPR-s would be 
highly favorable to Indian manufacturers and market 
to expand the segment of traditional pharmaceuticals 
as a rival to the modern medical drugs.
Threats 
• Product patent regime poses serious challenge to do-
mestic industry unless it invests in R&D. 
• R&D efforts of Indian pharmaceutical companies 
can be hampered by the lack of enabling regulatory 
requirement. 
• Drug Price Control Order puts unrealistic ceilings on 
product prices and profitability and prevents phar-
maceutical companies from generating investible 
surplus. 
• Lowering of the tariff protection.
• The new excise duty regime threatens the existence 
of many small scale pharmaceutical units, especially 
in the states of Andhra Pradesh and Maharashtra, 
that were involved in contract manufacturing for 
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the larger, established players. These companies are 
now shifting their manufacturing from these states to 
other ones that enjoy tax holidays.
• Political will and direction is needed as well as ap-
propriate health policy. Government should take 
the advantage of global funding mechanisms to en-
courage contributions from high income countries, 
partially financing the medical programs which help 
in the reduction of costs borne by the poor people. 
Steps have to be taken to utilize the capacity of cheap 
drugs available in the market and encouraging pub-
lic private partnerships and using effectively TRIPS 
flexibilities are some of the key steps to be looked 
into. Formulating alternative intellectual property 
strategies and looking into possibilities of amend-
ments should be looked into.
Conclusions
India has a matured pharmaceutical industry and 
the challenges are formidable after the accession to the 
TRIPS agreement. Besides engaging in a constant pro-
cess of reviewing the newly amended Patents Act, India 
would have to take complementary measures to ensu-
re that the pharmaceutical firms are not able to secure 
benefits that run contrary to the fundamental objective 
of providing access to medicines at affordable prices. 
A legal regime for preventing misuse of patent mono-
poly would be an essential component of such measu-
res. The structure of the patent regime and the nature 
of its impact on prices of pharmaceutical products may 
require initiatives that are beyond the scope of the patent 
legislation. The controversial issue of statutory control 
over the prices of drugs becomes relevant in this context. 
But above all, the developing countries would need to 
ensure that their TRIPS-consistent patent laws provide 
the balance of rights and obligations.
The TRIPS agreement has positively influenced the 
Indian pharmaceutical industry in terms of orienting it 
towards well developed markets. But on the other hand, 
the Indian drug manufacturers have been major suppliers 
of medicines both for India and for many low-income 
countries of Africa. Generics have been the mainstay of 
India’s production and they have been responsible for 
cutting down prices of many drugs. The chances of inno-
vation related to the novel drugs have been slim in India 
and they would remain so until the developed world kee-
ps its promise to invest into neglected diseases. Around 
the world, people are in need of medicines and most of 
them live in the low-income countries. If the curbs on 
affordable generic drugs keep on going, then the existing 
lack of access would only deteriorate further. 
The issue of the IPR is particularly relevant in case 
of HIV and AIDS. HIV is killing millions of people in 
countries already ravaged by wars, famine and poverty, 
countries which even lack the basic facilities to provide 
treatment to their infected citizens. The excessive IPR 
provisions in India could have also the negative impact 
on health care systems. It is argued that these provisions 
were not followed by any developed country during 
its economic development and they will form a heavy 
burden on the weak, developing economies. Despite the 
achievements in overall progress and economic reforms 
of the last decade, India could loose a “golden opportu-
nity” to create and advance India’s health care system 
in order to provide health care services and drugs for 
people who need them so desperately. 
Persisting with tough patent protection to drugs, 
as stated in TRIPS, could end the India’s public health 
care system’s capacity to provide all the necessary and 
life-saving drugs to its population and it would prevent 
other developing countries (especially in Africa) from 
ever achieving health care coverage and affordable drugs 
provision. It is often argued that the IPR provisions of 
the TRPIS benefit only a handful of large pharmaceuti-
cal corporations, at the cost of the health of millions of 
citizens. The sensitive IPR issues imposed by the gover-
nment of the people, by the people and for the people, 
are being run by a handful of corporations that are de-
sperate to protect their profits. Such aggressive tactics, at 
the expense of social welfare in a region that desperately 
needs it, do not serve the developed nations interests in 
the long run as they diminish their moral standing in 
the world. Finally, the world has to find a striking chord 
which would be able to provide the essential medicines 
for the poor and at the same time to provide incentives 
for innovation. Until this is achieved, millions of people 
in developing nations will die without life-saving drugs 
and millions of people will be getting over-medicated in 
the developed world.
Streszczenie:
Wpływ ochrony praw własności intelektualnej na rynek 
leków w Indiach
Słowa kluczowe: prawa własności intelektualnej, IPR, TRIPS, rynek 
leków, dostępność leków 
Artykuł opisuje wpływ, jaki na system opieki zdrowotnej w Indiach 
wywiera realizacja ochrony praw własności intelektualnej w obszarze 
leków. Wpływ porozumień TRIPS na innowację farmaceutyczną, do-
tąd uważany głównie za pozytywny, jest obecnie poddawany analizom 
i dyskutowany. Porozumienia TRIPS w dużej mierze pomogły rozwinąć 
przedsiębiorczość w Indiach i wpłynęły na zorientowanie jej na rynki 
krajów rozwiniętych. Przemysł farmaceutyczny w Indiach przeszedł ewo-
lucję trójfazową, w latach 70. ubiegłego wieku rozwijając się praktycznie 
od podstaw. Obecnie indyjska produkcja farmaceutyczna zaspokaja pra-
wie 95% potrzeb lekowych całego kraju. Na podstawie schematu SWOT 
w artykule przeprowadzono analizę wpływu TRIPS na indyjski przemysł 
farmaceutyczny.
References:
1. WHO, Public health Innovation and Intellectual Pro-
perty Rights, Report of the Commission on Intellectual 
Property Rights, Innovation and Public Health. Geneva 
2006 (http://www.who.int/immunization/newsroom/
Global_imm_data_October2006_revised.pdf)
2. The Malaria Research and Development Alliance, 2005 
accessed on 24.12.2007 (http://www.malariaalliance.org/
PDFs/RD_Report_complete.pdf).
Zeszyty Naukowe Ochrony Zdrowia. Zdrowie Publiczne i Zarządzanie58
leki za granicą
3. Press Release WHO/28 25 April 2000, Economic costs of 
malaria are many times higher than previously estimated 
(http://www.who.int/inf-pr-2000/en/pr2000-28.html)
4. Chadha V.K., Tuberculosis epidemiology in India: a re-
view; “Int. J. Tuberc. Lung. Dis.” 2005, 9(10):1072–1082.
5. AIDS epidemic update, UNAIDS, 2007, accessed 
on 27/12/2007 (http://data.unaids.org/pub/EPISlides 
/2007/2007_epiupdate_en.pdf).
6. Inter Press Service, Cheap Indian AIDS Drugs under 
cloud, United Nations Development Program, 2005: (http://
www.youandaids.org/Features/IndiaIPSNov2004.asp).
7. The10/90Report on Health Research 2003–2004, Global
Forum for Health Research, accessed on 30.12.2007. (http://
www.globalforumhealth.org/Site/002__What%20we%20 
do/005__Publications/001__10%2090%20reports.php).
8. Lopez A.D., Mathers C.D., Ezzati M., Jamison D.T., Murray
Ch.J.I., Measuring the Global Burden of Disease and Risk 
Factors, 1990–2001, Global Burden of Disease and Risk 
Factors, Oxford University Press, New York 2006.
9. WHO, Country Progress Indicators for Components of 
WHO Medicines Strat egy 2000–2003. WHO Medicines 
Strategy: Framework for Action in Essen tial Drugs and 
Medicines Policy. Geneva 2000.
10. DFID (U.K. Department for International Development), 
Access to Medicines in Underserved Markets: What 
Are the Implications of Changes in Intellectual Prop-
erty Rights, Trade and Drug Registration Policy? United 
Kingdom Government Policy and Plans, London 2004. 
Accessed on 30.12.2008 www.dfid.gov.uk/pubs/files/
dfidsynthesispaper.pdf
11. Bloom B.R., Michaud C.M., La Montagne J.R., Simonsen 
L. Priorities for Global Research and Development of 
Interventions. Disease Control Priorities in Developing 
Countries, 2nd ed. Oxford University Press, New York 
2006, p. 103–118.
12. Quick J.D. Ensuring access to essential medicines in the 
developing countries: A framework for action. “Clin. 
Pharm. Ther.” 2003; 73: 279–283.
13. Sein U.T., Rim P.C., TRIPS and access to medicines. 
“WHO Regional Health Forum” 2001; 5: 49–61.
14. WTO, 2006 accessed on 24.12.2007 (http://www.wto.org/
english/tratop_e/trips_e/factsheet_pharm00_e.htm)
15. Correa Carlos M., Intellectual Property Rights, the WTO 
and Developing Countries: The TRIPS Agreement and 
Policy Options, Zed Books Ltd, London and Third World 
Network, Malaysia 2000.
16. Maskus K., Intellectual property rights and economic de-
velopment. “Case Wes. J. Intellectual Property Law” 2000; 
32: 471.
17. WHO, Public Health Innovation and Intellectual Pro-
perty Rights, Report of the Commission on Intellectual 
Property Rights, Innovation and Public Health. Geneva 
2006; http://www.who.int/immunization/newsroom/
Global_imm_data_October2006_revised.pdf
18. World Health Organization, Globalization and access to 
drugs: Perspectives on WTO/TRIPS Agreement, “DAP 
Series”, No. 7, Geneva WHO. Action Program on Ethical 
Drugs, 1998, p. 58 (WHO/DAP/98.9).
19. Government of India, National Pharmaceutical Policy, 
2006 (http://chemicals.nic.in/npp_circulation_latest.pdf).
20. Abhay K., India in the Pharmaceutical Patents Regime 
– A Cost-Benefit Analysis.: (http://www.indiainfoline.
com/bisc/iprs.html)
21. http://www.ijp-online.com/temp/IndianJPharmacol383169_ 
134234.pdf
22. Organization of Pharmaceutical Producers of India, Annu-
al Report, accessed on 21.12.2007 (http://www.indiaoppi.
com/OPPI_41st_Annual_Report_Complete.pdf).
23. World Health Organization, Commission on Macroeco-
nomics and Health, Working Paper series WG4:3 (http://
www.emro.who.int/cbi/pdf/PatentedMedicines.pdf)
24. Biswajit D., Rao C.N., Transfer of Technology for Success-
ful Integration into the Global Economy: A case study of 
the Pharmaceutical Industry in India, UNCTAD/UNDP 
Programme on Globalization, Liberalization and Sustaina-
ble Development, United Nations, Geneva 2002.
25. Chaudhuri S., Growth and Structural Changes in the 
Pharmaceutical Industry in India, in: The Structure of 
Indian Industry (ed.), Anindya S., Subir G. Rajendra V., 
Oxford University Press, New Delhi 2002.
26. Report for national manufacturing competitiveness coun-
cil (NMCC), March 2005.Federation of India Chambers of 
Commerce and Industry (FICCI). http://www.ficci.com/
studies/pharma.pdf accessed on 20 Jan 2008.
27. Government of India, Mashelkar Committee Report (http://
cdsco.nic.in/html/Final%20Report%20mashelkar.pdf).
O autorach:
lek. med. Anees Ahmed Abdul Pari, MBBS, MPH, MScPH – jest ab-
solwentem międzynarodowych studiów magisterskich Euro pubhealth 
(Uniwersytet Sheffield – Uniwersytet Jagielloński); stażysta w szpitalu 
Manchester Royal Infirmary, Manchester (Wielka Brytania).
lek. med. Praveen Kumar Durgampudi, MD, MPH, MScPH – jest absol-
wentem międzynarodowych studiów magisterskich Europubhealth 
(Uniwer sytet Sheffield – Uniwersytet Jagielloński).
Anil Vaidya, MBBS, MPH, MScPH, Dipl. in Dermatology – jest absol-
wentem międzynarodowych studiów Europubhealth.
lek. Tomasz Bochenek, MPH – jest wykładowcą w Zakładzie Gospodarki 
Lekiem Instytutu Zdrowia Publicznego, Uniwersytet Jagielloński Colle-
gium Medicum, Kraków.
